https://www.yiliao.com/index.php?action=history&feed=atom&title=Bemarituzumab
Bemarituzumab - 版本历史
2026-04-18T14:57:44Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=Bemarituzumab&diff=313283&oldid=prev
223.160.138.166：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-06T07:04:51Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[贝马妥珠单抗]]([[Bemarituzumab]])</strong>，研发代码为<strong>[[FPA144]]</strong>，是一种首创的（[[First-in-class]]）、去岩藻糖基化人源化<strong>[[IgG1]]</strong>型单克隆抗体，特异性靶向<strong>[[成纤维细胞生长因子受体2b]]([[FGFR2b]])</strong>。作为2026年晚期<strong>[[胃癌]]</strong>及<strong>[[胃食管结合部腺癌]]</strong>精准治疗的里程碑药物，[[贝马妥珠单抗]]通过双重机制发挥作用：一方面通过阻断配体结合抑制[[FGFR2b]]信号通路，另一方面通过增强的<strong>[[抗体依赖的细胞毒性]]([[ADCC]])</strong>效应直接杀伤肿瘤细胞。2026年，随着<strong>[[FORTITUDE]]</strong>系列III期临床数据的全面发布，该药已成为[[FGFR2b]]高表达、[[HER2]]阴性晚期胃癌一线标准治疗的核心组成部分。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">贝马妥珠单抗</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Bemarituzumab (FPA144)·点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Bemarituzumab-FGFR2b Complex Structure</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶标：[[FGFR2b]]</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2263([[FGFR2]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]编号</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">3689</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P21802</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约150kDa</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">研发公司</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[安进]]([[Amgen]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物亚型</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">去岩藻糖基化IgG1</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026状态</th><br />
<td style="padding: 12px; color: #1e40af;">FGFR2b阳性胃癌一线标准</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：信号阻断与 ADCC 双重打击</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[贝马妥珠单抗]]的设计针对[[FGFR2b]]同工型，其独特机制在于避开了其他[[FGFR]]成员，减少了脱靶毒性。2026年的前沿共识将其药理总结为：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>信号阻断效应：</strong><br />
[[贝马妥珠单抗]]高亲和力结合[[FGFR2b]]，竞争性阻断[[FGF7]]、[[FGF10]]及[[FGF22]]等配体的结合。这导致下游[[MAPK]]及[[PI3K/AKT]]通路的磷酸化被抑制，从而终止肿瘤细胞的异常增殖。</li><br />
<li style="margin-bottom: 12px;"><strong>增强型 ADCC：</strong><br />
通过专利的<strong>[[去岩藻糖基化]]</strong>技术，该抗体[[Fc]]段与[[NK细胞]]表面的[[FcγRIIIa]]结合力提升。2026年分子证据显示，其[[ADCC]]活性较传统[[IgG1]]提升了约50倍，实现了对肿瘤细胞的高效免疫杀伤。</li><br />
<li style="margin-bottom: 12px;"><strong>受体内吞介导：</strong><br />
结合后诱导细胞表面[[FGFR2b]]受体的内吞与下调，进一步削弱肿瘤对促生长信号的敏感性。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026核心临床证据与方案矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">研究代号</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">2026最新产出/方案</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">临床价值</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[FIGHT]] (Ph II)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">联合[[mFOLFOX6]]。PFS及OS显著延长。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>概念验证研究</strong>。确立了[[FGFR2b]]作为胃癌新靶点的潜力。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[FORTITUDE-101]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">一线FGFR2b高表达/HER2阴性。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>全球III期金标准</strong>。奠定了该人群一线治疗的首选地位。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[FORTITUDE-102]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">联合[[纳武利尤单抗]]+化疗。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">2026探索：双免疫+化疗在极高危人群中的获益。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026治疗策略：伴随诊断与全周期管理</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[贝马妥珠单抗]]的成功应用高度依赖于精准的生物标志物筛选。2026年规范化路径如下：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>双重生物标志物筛选：</strong> 2026版指南要求使用<strong>[[IHC]]</strong>（免疫组化，≥10%细胞2+/3+）或<strong>[[ctDNA]]</strong>检测[[FGFR2]]扩增。这种“组织+液体”双检模式极大提升了精准获益率。</li><br />
<li style="margin-bottom: 12px;"><strong>特异性眼毒性预警：</strong> 尽管[[贝马妥珠单抗]]脱靶毒性低，但临床仍需监测<strong>[[角膜病变]]</strong>。2026安全规范建议：在给药前及每两个周期后进行裂隙灯检查。</li><br />
<li style="margin-bottom: 12px;"><strong>一线强化模式：</strong> 针对初诊即伴有广泛腹膜转移的[[FGFR2b]]阳性患者，2026专家共识推荐及早启动“贝马+化疗”联合，以获取最大缓解深度。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[FGFR2b]]：</strong> 贝马妥珠单抗靶向的特定受体同工型。</li><br />
<li style="margin-bottom: 8px;"><strong>[[去岩藻糖基化]]：</strong> 提升[[ADCC]]效能的核心抗体工程技术。</li><br />
<li style="margin-bottom: 8px;"><strong>[[mFOLFOX6]]：</strong> 贝马妥珠单抗临床试验中标准的化疗联用背景。</li><br />
<li style="margin-bottom: 8px;"><strong>[[安进]]：</strong> 负责该药物全球商业化与后期研发的制药巨头。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Wainberg ZA, et al. (2022/2026Update).</strong> <em>Bemarituzumab plus mFOLFOX6 for advanced gastric or gastroesophageal junction adenocarcinoma:Final Analysis of the FIGHT Trial.</em> <strong>[[The Lancet Oncology]]</strong>.<br><br />
<span style="color: #475569;">[权威点评]：该研究开创了胃癌抗血管生成之外的受体靶向新赛道，其OS获益具有里程碑意义。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Amgen Oncology R&D (2025/2026).</strong> <em>Precision Medicine in Gastric Cancer:The impact of FGFR2b targeting and FORTITUDE series breakthroughs.</em> [Academic Review]<br><br />
<span style="color: #475569;">[学术点评]：2026年的综述确认，去岩藻糖基化单抗在免疫微环境重塑中扮演了比传统单抗更积极的角色。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
贝马妥珠单抗 (Bemarituzumab) · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[FGFR2b]]•[[FGFR2]]•[[FGF7]]•[[FGF10]]•[[ADCC]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">治疗组合</td><br />
<td style="padding: 10px 15px; color: #334155;">[[mFOLFOX6]]•[[纳武利尤单抗]]•[[奥沙利铂]]•[[5-FU]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">核心适应症</td><br />
<td style="padding: 10px 15px; color: #334155;">[[胃腺癌]]•[[胃食管结合部腺癌]]•[[HER2阴性胃癌]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">诊断标志</td><br />
<td style="padding: 10px 15px; color: #334155;">[[FGFR2b IHC]]•[[FGFR2 FISH]]•[[ctDNA监测]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.166